179 related articles for article (PubMed ID: 22821003)
1. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Stief TW
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):619-21. PubMed ID: 22821003
[TBL] [Abstract][Full Text] [Related]
2. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Firriolo FJ; Hupp WS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):431-41. PubMed ID: 22668425
[TBL] [Abstract][Full Text] [Related]
3. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants.
Stief TW
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):265-9. PubMed ID: 17413764
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
5. Acute management of bleeding in patients on novel oral anticoagulants.
Siegal DM; Crowther MA
Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
[TBL] [Abstract][Full Text] [Related]
6. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
7. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
[TBL] [Abstract][Full Text] [Related]
8. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Baumann Kreuziger LM; Reding MT
Thromb Res; 2013 Aug; 132(2):e161-3. PubMed ID: 23916381
[No Abstract] [Full Text] [Related]
9. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Baglin T; Keeling D; Kitchen S;
Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
[No Abstract] [Full Text] [Related]
10. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Miller MP; Trujillo TC; Nordenholz KE
Am J Emerg Med; 2014 Apr; 32(4):375-82. PubMed ID: 24512886
[TBL] [Abstract][Full Text] [Related]
11. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
12. [New anticoagulants--are we prepared?].
Pawlikowska Z; Szponar J
Przegl Lek; 2012; 69(8):483-5. PubMed ID: 23243913
[TBL] [Abstract][Full Text] [Related]
13. [Role of new oral anticoagulants in interventional cardiology].
Brasselet C; Duval S
Ann Cardiol Angeiol (Paris); 2012 Dec; 61(6):453-6. PubMed ID: 23102941
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
[TBL] [Abstract][Full Text] [Related]
16. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
17. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
19. New oral anticoagulants: will they replace warfarin?
Little JW
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May; 113(5):575-80. PubMed ID: 22668618
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
